Quadrant Capital Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
DTC
Quadrant Capital Group's AXSM Position: Q2 2026 in Review
Quadrant Capital Group sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 135 shares — an estimated $22.8K sold.
Quadrant Capital Group first reported a position in AXSM in Q3 2020 and held it in 22 quarters. The position peaked at $24.7K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Quadrant Capital Group reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 135 Axsome Therapeutics shares in Q2 2026, an estimated $22.8K.
- Quadrant Capital Group first reported a position in Axsome Therapeutics in Q3 2020 and held it in 22 quarters.
- Quadrant Capital Group's Axsome Therapeutics position peaked at $24.7K in Q4 2025.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.